Close Menu

Agilent

Rna Diagnostics is hoping to make its RDA assay available as a laboratory-developed test for research use next year before offering it to clinicians in 2020.

The firm provided full-year 2018 revenue and adjusted earnings guidance that fell below Wall Street's expectations.

Agilent said the acquisition will enable it to provide consumers with a single informatics solution across laboratory and operational domains.

Three vendors applied their variant calling and interpretation pipelines to the same tumor NGS panel data and came up with overlapping but different results.

The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.

The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.

The companies will integrate Agilent's Seahorse XFe96/XFe24 Analyzers with BioTek's Cytation 1 Cell Imaging Multi-Mode Reader.

Pages

As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.

BBC News says the uncertainty over Brexit is affecting science funding in the UK.

A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.

In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.